Home › Companies › IMUX

Pipeline (4 active programs)

Technology platforms

Capital (as filed)

Cash

$155M cash and cash equivalents · Jun 30, 2026 (10-Q)

Operating cash flow

−$31.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$155M cash, runway late 2027 per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-08-12 UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 🔒 Paid
• 2026-05-28 Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Immunic, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-05-28 Watch Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products Strong smart-money signal and credible binary catalyst are offset by a Phase 2 PMS primary miss, generic Aubagio as pricing floor, fenebrutinib positive Phase 3 in both indications, and heavy warrant plus royalty stack; wait for ENSURE readouts before committing capital.
2. 2026-08-12 Watch UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 Watch list maintained as runway is now explicitly bridged to late 2027 and the commercial/regulatory team is complete, but fenebrutinib, generic Aubagio, the 5% royalty stack, and dilution overhang are unchanged, and the stock at $15.48 has compressed the pre-data asymmetry considerably.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-11 8-K in filings ↓

  • “If positive, Immunic plans to submit a New Drug Application (NDA) in the United States in mid-2027, with a targeted potential regulatory approval date in 2028. · Vidofludimus Calcium in Progressive MS: The planned initiation of a Phase 3 program in progressive MS remains on track for later this year. · IMU-381: The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune diseases, continues to be in preclinical testing with lead candidate identification ongoing.”

    matched to vidofludimus calcium (IMU-838) · topline data · read as mid-2027

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (33)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 5, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Nov 2, 2026ReleaseImmunic to Participate in Investor Conferences in November
• Oct 29, 2026ReleaseImmunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
• Oct 21, 2026ReleaseImmunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → IMUX pipeline
• Oct 19, 2026ReleaseImmunic Appoints Jaa Roberson as Chief People Officer
• Oct 7, 2026ReleaseImmunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → IMUX pipeline
• Sep 11, 20268-KCurrent report: officer / director change
• Sep 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Sep 2, 2026ReleaseImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
• Sep 1, 2026ReleaseImmunic Appoints Chitrang Davé as Chief Data and Digital Officer
• Aug 11, 2026ReleaseImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → IMUX pipeline
• Aug 11, 20268-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
• Aug 11, 202610-QQuarterly report
• Aug 10, 2026ReleaseImmunic Appoints Elena Ridloff to Board of Directors
• Jul 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Jul 6, 20268-KCurrent report: officer / director change
• Jun 29, 20268-KCurrent report: officer / director change, shareholder vote
• May 29, 2026DEF 14AProxy statement
• May 28, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• May 27, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
• May 19, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
• May 13, 20268-KCurrent report: results of operations · EX-99.1
• May 13, 202610-QQuarterly report
• Apr 30, 2026S-3/AShelf registration (amended)
• Apr 28, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
• Apr 23, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events · EX-99.1
• Apr 22, 202610-K/AAnnual report (amended)
• Apr 14, 20268-KCurrent report: shareholder vote, other events
• Apr 10, 20268-KCurrent report: officer / director change
• Apr 2, 2026S-3Shelf registration
• Apr 1, 20268-KCurrent report: other events · EX-99.1
• Mar 31, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
• Mar 2, 2026DEF 14AProxy statement